...
【24h】

Potential Role of Induced Pluripotent Stem Cells as Regenerative Medicine in Retinal Cell Damage

机译:诱导多能干细胞作为视网膜细胞损伤中的再生药物的潜在作用

获取原文
获取原文并翻译 | 示例
           

摘要

Induced pluripotent stem cells (also called iPSCs) are somatic cells reprogrammed by overexpressing four nuclear transcriptional factors containing Sox2, Klf4, c-myc and Oct4 is the one of research hotspots. Its pluripotency, self-renewal capacity and wide accessibility to donor tissues have made possible the means for modified regenerative medicine. They are considered a possible basis of healthy tissue to cure diseases, like ophthalmic diseases, degenerative diseases, age-related macular degeneration (AMD), are primarily because of the weakening capability of photoreceptor cells, retinal ganglion cells (RGCs), retinal pigmented epithelium (RPE) or other retinal cells. And these retinal cells are unable to regenerate and currently there are no effective treatments to restore sight. iPSCs allow for the in vitro development of numerous varieties of retinal cells, and may treat these diseases by retinal transplantation. Although other stem cells could differentiate into retinal cells, iPSCs derived retinal cells might have numerous benefits as compared to other stem cell sources including embryonic stem (ES) cells. Mainly they would be directly obtained from the patient, therefore eradicating every probable chance of adverse immune responses. Second, making iPSCs just needs somatic cells, thus circumventing the valid ethical issues which limited the clinic use of ES cells derived from human. Third, iPSCs are parallel to ES cells in differentiation ability, they can be expanded in vitro and induced to differentiate into retinal cells, providing a renewable source for therapeutic applications and scientific researches. In this current review, we have concise latest progresses.
机译:诱导多能干细胞(也称为IPSC)是通过过表达含有SOX2,KLF4,C-MYC和OCT4的四种核转录因子重编程的体细胞是研究热点之一。其多能性,对供体组织的自我更新能力和广泛的可及性使得改性再生药物的手段成为可能。它们被认为是健康组织的治疗疾病的基础,如眼科疾病,退行性疾病,年龄相关的黄斑(AMD),主要是因为感光体细胞的能力弱化,视网膜神经节细胞(RGC),视网膜色素上皮上皮(RPE)或其他视网膜细胞。这些视网膜细胞无法再生,目前没有有效的治疗恢复景点。 IPSCS允许众多各种视网膜细胞的体外发展,并且可以通过视网膜移植治疗这些疾病。虽然其他干细胞可以分化为视网膜细胞,但与包括胚胎茎(ES)细胞的其他干细胞来源相比,IPSCs衍生的视网膜细胞可能具有许多益处。主要是它们将直接从患者获得,因此消除了不良免疫反应的所有可能的可能性。其次,使IPSCS仅需要体细胞,因此避免了有效的伦理问题,这些问题限制了来自人的ES细胞的临床使用。第三,IPSCS在分化能力中平行于ES细胞,它们可以在体外扩增并诱导以区分视网膜细胞,为治疗应用提供可再生源和科学研究。在此次审查中,我们简明扼要的最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号